Alerta

DEVICE FOR DISTRIBUTING AND RECEIVING A HETEROGENEOUS POPULATION OF PANCREATIC CELLS, METHOD AND BIOREACTOR

Resumen de: WO2026131972A1

The invention relates to a device for distributing and receiving a population of pancreatic islets heterogeneous in size, the device comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving the pancreatic cells, the opening leading out onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (I) taken along the section Si, the device being configured such that the widths of the opening of two adjacent channels have an equal or increasing value moving away from the center O and such that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value moving away from the center O. The invention relates to the field of implantable devices, in particular artificial pancreas devices.

CANCER SCREENING METHOD

Resumen de: WO2026137021A2

A cancer screening method takes advantage of the Warburg Effect to provide an early detection method and system. The cancer screening method includes administering a glucose solution, such as a C-13 glucose solution, measuring a metabolized lactate level in the blood of the individual after a period of time following the administration of the glucose solution, and comparing the measured lactate level to a baseline lactate level representative of noncancerous activity, and making a determination as to whether or not the measured lactate level is potentially indicative of cancer activity in the individual. The period of time is selected to be an amount of time following the glucose administration after which metabolized lactate from cancerous cells would be present in the blood and before which the metabolized lactate would be cleared or substantial amounts of non-cancerous metabolized lactate would be present in the blood of the individual.

ANALYTE PATTERN ANALYSIS

Resumen de: US20260174959A1

0000 A glucose data analysis system includes an on-body unit and a processor. The on-body unit is configured to measure glucose levels of a user. The processor is configured to receive therapy data of the user including glucose data monitored by the on-body unit, analyze daily glucose profiles of the glucose data over an analysis period by a machine learning model, group the daily glucose profiles into two or more patterns based on the analysis performed by the machine learning model, and output a report including identification of the two or more patterns associated with each daily glucose profile. Advantageously the system may identify and visualize patterns of glucose data, identify recurring patterns, identify correlations between patterns and external events (e.g., medication, meals, exercise, sleep, stress, etc.), reduce glycemic variability, streamline analysis with unsupervised machine learning (e.g., no training), and provide recommendations for user intervention or actions based on identified patterns.

APPLICATOR DEVICE FOR INSULIN PATCH PUMP WITH CANNULA DEPTH CONTROL

Resumen de: US20260174953A1

Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. According to one aspect, an applicator device includes a cannula and an insertion needle configured to insert the cannula into a body of a user. The applicator can include features that control the geometry of the skin during insertion of the cannula to provide a more reliable depth and insertion angle for the cannula.

MAGNETIC RESONANCE IMAGING OF SUGAR MOIETIES AND PH IN METABOLIC DYSFUNCTION

Resumen de: WO2026136617A1

Provided herein is a noninvasive method for measuring pH, glucose and glycogen levels using a single acquisition method, as well as systems for performing the method. This method for glycogen/glucose (and pH) detection has high specificity enabled by superior chemical shift separation in high-strength magnetic fields. The methods have applications in detecting changing tumor microenvironments in cancerous cells for measuring important metrics for noninvasive and quantitative metabolic profiling.

METHOD FOR IMPROVED SENSOR SENSITIVITY OF A MICRONEEDLE-BASED CONTINUOUS ANALYTE MONITORING SYSTEM

Resumen de: US20260174360A1

Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. Each microneedle of the microneedle array may include a microneedle body, an electrode material on the microneedle body, a biorecognition layer on the electrode material, a diffusion-limiting layer on the biorecognition layer, an interferent blocking agent, and/or an attachment enhancer between the biorecognition layer and the diffusion-limiting layer, where the interferent blocking agent and the attachment enhancer are configured to improve sensor sensitivity variability.

INHIBITOR FOR GLUCOSE UPTAKE INTO RED BLOOD CELLS, SUPPRESSANT FOR GLUCOSE CONCENTRATION REDUCTION IN BLOOD-COLLECTING TUBE, AND BLOOD-COLLECTING TUBE INCLUDING SAME

Resumen de: US20260177565A1

0000 An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE

Resumen de: US20260174960A1

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

MEDICINE INJECTION AND DISEASE MANAGEMENT SYSTEMS, DEVICES, AND METHODS

Resumen de: US20260174969A1

0000 Diabetes management systems may include a glucose monitoring device adapted to transmit glucose data and at least one accessory in communication with the glucose monitoring device and adapted to provide at least one alarm or alert based on the glucose data.

METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION

Resumen de: US20260174803A1

0000 The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability.

SYSTEMS AND METHODS FOR OPTIMIZING MEDICAMENT DOSING

Resumen de: US20260174961A1

A system for monitoring a patient includes one or more processors and a sensor device implemented in circuitry. The system is configured to measure, using the sensor device, a blood glucose status of the patient, and determine, using one or more processors, an initial insulin dose for the patient based on the blood glucose status of the patient. The system is further configured to optimize the initial insulin dose for the patient, based at least in part on a correction factor, to create an optimized insulin dose for the patient. The system is configured to facilitate therapy, using the one or more processors, based on the determined optimized insulin dose.

GLUCOSE ALERT PREDICTION HORIZON MODIFICATION

Resumen de: US20260174399A1

Data describing glucose measurements is received from a continuous glucose monitoring (CGM) system worn by a user and predicted glucose values during a future time period are generated for the user based on the data. A determination is made that at least one of the predicted glucose values satisfies a threshold value for an alert, which is associated with a prediction horizon that defines an amount of time prior to satisfaction of the threshold value for communicating the alert to the user. Output of the alert is caused responsive to determining that the at least one predicted glucose value satisfies the threshold value for the alert within the prediction horizon, relative to a current time. The prediction horizon is modified based on a user response to the alert. Output of a subsequent instance of the alert is caused based on the modified prediction horizon.

CONTEXTUAL INPUT SYSTEM FOR AUTOMATED INSULIN DELIVERY

Resumen de: US20260174954A1

0000 An insulin delivery system for diabetes management includes a patch-based insulin pump configured to deliver insulin to a user, a user input button disposed on the patch-based insulin pump, a processor configured to execute a hybrid closed loop algorithm that automatically controls insulin delivery based on glucose levels. The user input button is configured to receive user input comprising a sequence of button presses that communicate contextual information about user activities to the hybrid closed loop algorithm, the contextual information being distinct from direct insulin bolus delivery commands. The contextual information may include meal intake, physical activity, and sleep status communicated through different sequences of button presses. The system includes confirmation mechanisms that provide feedback and allow cancellation of inputs, enabling discrete real-time communication of personalized data to enhance diabetes management.

CLOSED-LOOP BLOOD GLUCOSE CONTROL SYSTEMS AND METHODS

Resumen de: EP4765154A2

0001 An automated closed-loop blood glucose control system comprises a continuous glucose-monitoring sensor (101), a subcutaneous insulin delivery device (103); and a controller (105) which determines a maximal allowable insulin injection amount and determines an insulin delivery control signal on the basis of the maximal allowable insulin injection amount and the quantity of insulin to inject.

BLOOD GLUCOSE MANAGEMENT METHOD, USER INTERFACE, AND RELATED APPARATUS

Resumen de: EP4765156A1

A blood glucose management method, a user interface, and a related apparatus are provided. According to the blood glucose management method, a first meal time can be determined based on historical blood glucose values of a user; a second meal time can be determined based on one or more of the following: a meal time input by the user, a hand movement of the user, and a heart rate of the user; and a third meal time can be determined based on the first meal time and the second meal time, where the third meal time is used to evaluate a blood glucose health status of the user. A meal time of the user is predicted based on historical meal times of the user that are determined in a plurality of manners, so that an electronic device can evaluate a blood glucose status of the user more accurately.

GLUCOSE SENSOR IDENTIFICATION USING ELECTRICAL PARAMETERS

Resumen de: EP4763078A2

An example method for calibrating a glucose sensor includes determining, by one or more processors, a set of electrical parameters for the glucose sensor of a plurality of glucose sensors and determining, by the one or more processors, a cluster for the glucose sensor based on the set of electrical parameters. Each cluster of the plurality of clusters identifies respective configuration information. In this example, the method includes configuring, by the one or more processors, the glucose sensor to determine a glucose level of a patient based on configuration information identified by the determined cluster.

DYNAMIC ADJUSTMENT OF A CORRECTION FACTOR OF A USER BASED ON GLUCOSE VALUES

Resumen de: WO2025038566A1

The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.

Systems and methods for analyzing blood glucose and changing human behavior

Resumen de: US12665067B1

Methods and systems are described for a computer-implemented method for managing behavior in a subject, the method comprising: monitoring a plurality of behavioral events, each event being correlated to a timestamp within a time period; identifying a pattern in the plurality of behavioral events; generating, based on the identified pattern, personalized content for the subject; generating one or more nudges for the subject based on the personalized content, wherein the one or more nudges comprise prompts or suggestions aimed at encouraging adherence to executing suggested behavior changes provided in the personalized content; and causing presentation of the personalized content and the one or more nudges to the subject.

BLOOD GLUCOSE CONTROL SYSTEM

Resumen de: WO2021011738A1

A glucose level control system can autonomously modify therapy provided to a subject based on a comparison of the effect of different values for a control parameter. The system can deliver therapy to the subject during a first therapy period using a first value for the control parameter and determine a corresponding first effect to the first therapy by analyzing glycemic control of blood glucose in the subject. The system may autonomously generate a second value for the control parameter, and determine a second effect corresponding to a second therapy provided during a second time period using the second value. By comparing the effects of the two therapy periods, a value for the control parameter that provides improved blood glucose level management can be determined.

NOVEL SNAP PEA VARIETY SUGAR 204

Resumen de: US20260144222A1

0000 The present invention provides novel snap pea cultivar Sugar 204 and plant parts, seed, and tissue culture therefrom. The invention also provides methods for producing a pea plant by crossing the pea plants of the invention with themselves or another pea plant. The invention also provides pea plants produced from such a crossing as well as plant parts, seed, and tissue culture therefrom.

INSULIN PATCH PUMP SYSTEM WITH IMPROVED FLUIDIC CONNECTION

Resumen de: US20260166221A1

Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.

CELL THERAPY FOR DIABETES IN TRANSPLANT RECIPIENTS

Resumen de: WO2026128361A1

Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.

IDENTIFYING POTENTIAL ANALYTE SENSOR FAULTS THROUGH INTERACTION WITH AMD SYSTEMS

Resumen de: US20260166226A1

Presented is a medicament delivery system including a controller, a wearable medication delivery device, an analyte sensor, and other devices. In an example, a receiver is operable to receive glucose measurement values from the analyte sensor. A number of devices of the medicament delivery system may include a processor operable to execute programming code and to identify anomalous readings among the received glucose measurement values. The identified anomalous reading may, for example, be based on the received glucose measurement values violating a measurement change threshold indicative of abnormal sensor behavior. The processor may be operable to, in response to identifying the anomalous reading, revert a medicament delivery setting to a default safety basal delivery setting and/or generate a notification, an inquiry, and/or an alert for presentation to a user.

APPLICATOR DEVICE FOR INSULIN PATCH PUMP WITH IMPROVED SAFETY FEATURES

Resumen de: US20260166220A1

0000 Embodiments disclosed herein are directed to an applicator for inserting a cannula into a body of the user for delivering medication from a medication infusion device to the user. Features of the applicator device provide a more reliable, secure and safe insertion process.

MEASUREMENT MODULE AND MEASUREMENT SYSTEM

Nº publicación: WO2026126865A1 18/06/2026

Solicitante:

SONY SEMICONDUCTOR SOLUTIONS CORP [JP]
\u30BD\u30CB\u30FC\u30BB\u30DF\u30B3\u30F3\u30C0\u30AF\u30BF\u30BD\u30EA\u30E5\u30FC\u30B7\u30E7\u30F3\u30BA\u682A\u5F0F\u4F1A\u793E

Resumen de: WO2026126865A1

The present disclosure pertains to a measurement module and a measurement system with which it is possible to achieve highly accurate measurement of glucose levels. This measurement module includes a plurality of sensors to be attached to a human body via electrodes. In the measurement module, a measurement unit inputs RF signals to at least any one of the sensors to measure reflected signals and transmitted signals, and on the basis of these measured signals, outputs glucose calculation information for calculating a glucose level in the human body. The present disclosure is applicable to wearable devices such as smartwatches.